Advancing a Pipeline

Our expanding pipeline of Probody® therapeutics is built on a robust portfolio of proprietary and patented technology. Rooted in innovation and differentiation, and driven by our vision and mission, we are advancing a deep oncology pipeline of Probody therapeutics by blazing our own trail and in partnership with some of the world’s leading biopharmaceutical companies.

Research & development

Product Candidate
Indication
Discovery
LEAD Optimization
IND-Enabling
Phase 1
Phase 2
Commercial Rights
Info
+ CX-2009*
ER/PR Positive, HER2 Negative Breast Cancer
CD166 Probody drug conjugate
CytomX Therapeutics
Info
+ BMS-986249
Metastatic Melanoma
CTLA-4 Probody immunotherapy
BMS-986249 - Partner Logo
Info
+ CX-2029
Solid Tumors
CD71 Probody drug conjugate
CX-2029<span class='symbol'>†</span> - Partner Logo CytomX Therapeutics
Info
+ BMS-986288
Solid Tumors
CTLA-4 NF Probody Immunotherapy
BMS-986288 - Partner Logo
Probody Drug
Conjugate
TBA
EpCAM PDC
CytomX Therapeutics
T Cell Bispecific
TBA
EGFR-CD3 TCB
T Cell Bispecific - Partner Logo CytomX Therapeutics
T Cell Bispecific
TBA
CD3 TCB
T Cell Bispecific - Partner Logo CytomX Therapeutics
Additional PDCs, IO, TCBs
TBA
CytomX Therapeutics
Info
+ CX-072
(+ Ipilimumab)
Relapsed Refractory Melanoma
PD-L1 Probody immunotherapy
CytomX Therapeutics
Info
+
  • Immunotherapies
  • Probody drug conjugates
  • T cell engaging bispecifics
  • Multiple programs

*CytomX is instituting a temporary pause to the enrollment and conduct of the CX-2009 clinical program, per press release dated March 30, 2020.

†CytomX and AbbVie are finalizing next steps for the advancement of CX-2029 into Phase 2 expansion cohorts, per press release dated March 30, 2020.

Lead candidates

We are utilizing our Probody® platform to develop potential best-in-class immunotherapies against clinically validated targets and potential first-in-class therapeutics against novel, difficult-to-treat drug targets. We expect our Probody therapeutics have the potential to:

  • Overcome toxicity challenges associated with many current treatments
  • Enhance the efficacy and safety of combination regimens used to treat cancer
  • Expand the universe of possible drug targets previously considered inaccessible to traditional antibody drug conjugates
  • Offer new more powerful treatment options, especially for patients underserved by current therapies

CX-2009 (CD166-directed Probody drug conjugate)

The PROCLAIM-CX-2009 study is a Phase 1/2 clinical trial evaluating CX-2009 as monotherapy in patients with select advanced solid tumors, including breast cancer, castration-resistant prostate cancer, cholangiocarcinoma (bile duct cancer), endometrial cancer, head and neck cancer, non-small-cell lung cancer and ovarian cancer.

While CD166 is widely and highly expressed on solid tumor cells, it has been previously considered “undruggable” given its expression on normal tissues. In preclinical studies, Probody drug conjugates targeting CD166 have led to complete regressions in models of breast and lung cancer at therapeutically relevant doses, and are well tolerated in non-human primates. CX-2009 has been conjugated with DM4, a highly potent cytotoxic drug. DM4 is developed by and licensed from ImmunoGen.

BMS-986249 (CTLA-4-directed Probody therapeutic)

Bristol Myers Squibb is enrolling patients in a Phase 1/2 clinical trial to evaluate a CTLA-4-directed Probody therapeutic alone or in combination with Opdivo® (nivolumab) in solid cancers that are advanced or have spread.

CTLA-4, a clinically validated inhibitory immune checkpoint protein, is the most advanced target from the 12-target collaboration.

CX-2029 (CD71-directed Probody drug conjugate)

CytomX and AbbVie are co-developing a PDC directed against CD71, the transferrin receptor that is highly expressed on a number of solid and hematologic tumors, as well as many normal tissues. CytomX is evaluating CX-2029, a CD71-directed Probody drug conjugate, in a Phase 1/2 clinical trial as monotherapy.

CD71 is an excellent “internalizer,” which has the potential to efficiently deliver toxin to tumor cells. Historically, CD71 has not been widely pursued as a target given its expression on normal tissues and potential for causing toxicities. CytomX presented proof-of-concept data at AACR in 2016 demonstrating the creation of a therapeutic window for a CD71-targeting PDC.

BMS-986288 (CTLA-4-directed Probody therapeutic)

Bristol Myers Squibb is enrolling patients in the dose escalation phase of a Phase 1/2a clinical trial (NCT03994601) of a second anti-CTLA-4 Probody, BMS-986288, based on a modified version of Yervoy® (ipilimumab), to evaluate a CTLA-4-directed Probody therapeutic alone or in combination with Opdivo® (nivolumab) in patients with selected advanced solid cancers.

CTLA-4, a clinically validated inhibitory immune checkpoint protein, is the most advanced target from the 12-target collaboration.

CX-072 (PD-L1-targeting Probody therapeutic)

CX-072 is a wholly owned PD-L1-targeting Probody therapeutic for the treatment of cancer. Initial clinical data presented at the ASCO and ESMO 2018 Annual Meetings showed that CX-072 demonstrated tolerability and anti-tumor activity, while reducing activation of the immune system outside the tumor.

Initial clinical translation data presented at SITC confirmed that CX-072 is unmasked, activated and has biological activity in patient tumors while remaining predominantly masked and intact in circulation. Following a recent program and portfolio prioritization, CytomX has also made the strategic decision to terminate the Phase 2 trial of the anti-PD-L1 Probody CX-072 in combination with Yervoy® (ipilimumab) in melanoma. This allows CytomX to focus on its potential first-in-class assets, including the combination of CX-072 and CX-2009.

CX-188 (PD-1-targeting Probody therapeutic)

CX-188 is our wholly owned PD-1-targeting Probody therapeutic. As with anti-PD-L1 therapies, PD-1 monotherapy and combinations have been associated with significant toxicities. Our preclinical studies have shown that CX-188 has the potential for an improved therapeutic index relative to PD-1 antibodies. The IND for CX-188 was cleared by the FDA. 

Following a program and portfolio prioritization, CytomX has decided to indefinitely postpone the clinical trials of CX-188, a PD-1 Probody. CytomX may elect to initiate clinical trials of CX-188 in the future.

Clinical trials

Our most promising drug candidates are currently in clinical trials, investigating their potential utility in a number of advanced or recurrent solid tumors or lymphomas.

Learn More

Access information for healthcare providers & patients

Learn More